Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy Jeffrey J. Jackson , Grant M. Shibuya , Buvana Ravishankar , Lavanya Adusumilli , Delia Bradford , Dirk G. Brockstedt , Cyril Bucher , Minna Bui , Cynthia Cho , Christoph Colas , Gene Cutler , Adrian Dukes , Xinping Han , Dennis X. Hu , Scott Jacobson , Paul D. Kassner , George E. Katibah , Michelle Yoo Min Ko , Urvi Kolhatkar , Paul R. Leger , Anqi Ma , Lisa Marshall , Jack Maung , Andrew A. Ng , Akinori Okano , Deepa Pookot , Daniel Poon , Chandru Ramana , Maureen K. Reilly , Omar Robles , Jacob B. Schwarz , Anton A. Shakhmin , Hunter P. Shunatona , Raashi Sreenivasan , Parcharee Tivitmahaisoon , Mengshu Xu , Thant Zaw , David J. Wustrow , Mikhail Zibinsky JOURNAL OF MEDICINAL CHEMISTRY（2022）
Key words
potent gcn2 inhibitor capable, vivo efficacy, mdsc-driven, anti-angiogenesis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
